Introduction
The literature search was conducted using PubMed (www.ncbi.nlm.nih.gov/sites/entrez), entering the search term 'cystic fibrosis', for the period 13 November 2007 to 1 November 2008. There were 1380 papers identified, and when limits were set for 'clinical trial' and 'randomized controlled trial' this left 44 papers. In addition, three meta{analyses and three practice guidelines were identified. The papers selected for this review are a personal choice of studies with important or interesting clinical messages.
Clinical trials PTC124
(1) Kerem E, Hirawat S, Armoni S, et al.
Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 2008;372:719-27
What is already known? + A nonsense mutation, also known as a premature stop codon, is a single point alteration in DNA, which converts an amino acid{encoding codon to a translational stop codon (UAA, UAG, or UGA in the mRNA). Premature stop codons cause premature cessation of translation, hence result in truncated protein products, and when this results in loss of function or reduced activity, it can cause disease. + When the protein product is Cystic Fibrosis Transmembrane Regulator (CFTR), cystic fibrosis ensues. The mutation leads to little functional CFTR so the CF phenotype is usually severe.
+ Worldwide, about 10% of patients (estimated 7000 individuals) carry at least one CFTR nonsense mutation. Commoner in Ashkenazi Jews, it accounts for 50% of CF patients in Israel. The commonest of these gene mutations are G542X and W1282 X. + Certain aminoglycoside antibiotics (e.g. gentamicin) can induce ribosomes to read through a premature stop codon in mRNA leading to continuation of translation and production of the complete protein. Topical application of gentamicin in the nose has been shown to lead to an increase in CFTR{ mediated chloride transport. 1 + PTC124 is an oral (non{aminoglycoside) drug that was identified via high throughput screening. It was produced specifically to induce ribosomes to read through premature stop codons but not normal stop codons. Mouse work showed it generated production of functional CFTR, and phase I studies established its safety profile.
Methods + Four centres in Israel participated in a phase II open label prospective trial. Study sponsored by PTC Therapeutics and part funded by CF Foundation Therapeutics. + Adults with at least one nonsense mutation were recruited. All had an FEV 1 R40 % predicted and an oxygen saturation R92%. + They were given PTC124 at a dose of 14 mg/kg/day (in three divided doses) for 14 days, and then had 14 days without. In the second cycle the dose was 40 mg/kg/day with the same timings. + The primary outcomes were change in CFTR{mediated total chloride transport;
proportion of patients who responded to treatment; and normalization of chloride transport.
Results + Twenty{three patients with median age 25 years were assessed in the first cycle and 21 in the second cycle. Median FEV 1 was 65% (range 41-117%). + Mean total chloride transport increased in the first treatment phase, with a change of −7.1 (SD 7.0) mV (p<0.0001), and in the second, with a change of −3.7 (SD 7.3) mV (p=0.032). A response in total chloride transport (defined as a change in nasal PD of −5 mV or more) was recorded in 16/23 patients in the first cycle's treatment phase (p<0.0001) and in 8/21 patients in the second cycle (p<0.0001). Total chloride transport entered the normal range for 13/23 patients in the first cycle's treatment phase (p=0.0003) and for 9/21 in the second cycle (p=0.02). + The drug was well tolerated, with constipation and mild dysuria the principle adverse effects.
Critique + This is a potential major breakthrough for CF patients with nonsense mutations, as in many patients PTC124 shifted chloride transport into the normal range. + However there was no dose response noted, although the authors suggest that may be because the lower dose may have been at the upper end of the dose response curve anyway. + There was also no correction noted in sweat chloride concentrations. + Phase III trials are now required to assess clinical outcomes, and these should include children. Cost effectiveness must also be considered. + If these are successful, it is important the drug is made available soon and at an affordable price for the health services. What is already known?
Nebulized aztreonam lysine -two studies
+ Pseudomonas aeruginosa is the predominant pathogen infecting 80% of CF patients by 18 years, is associated with accelerated decline in lung function and is a significant predictor of mortality. + Inhaled antipseudomonal antibiotics are widely used although choices are limited, principally to colomycin and tobramycin. + Aztreonam is a monobactam with a wide spectrum of activity against aerobic gram negative bacteria, and has proved useful as an intravenous treatment for P. aeruginosa. The parenteral solution contains arginine, which causes airway inflammation after long{term use in CF patients. + AZLI is the lysine salt of aztreonam and has been developed for aerosol use. A phase 1b study showed it to be safe in adults and adolescents with CF. 2 Methods + Double{blind randomized placebo controlled phase II study in 20 CF centres in USA. Study part sponsored by pharmaceutical company Gilead Sciences Inc. + AZLI (or placebo) at a dose of 75 mg or 225 mg was given twice daily for 14 days using an eFlow® nebulizer. + Adults and adolescents R13 years, with FEV 1 R40% predicted, oxygen saturation >90%, chronic P. aeruginosa infection and no antipseudomonal antibiotics for previous 56 days were recruited. Results + There were 211 participants with mean age 26 years (78% were aged R18 years) and mean FEV 1 55% predicted. Of these, 70% were on long{term azithromycin. + AZLI increased median time for need of inhaled/intravenous antipseudomonal antibiotics for symptoms of an exacerbation by 21 days compared to placebo (92 vs 71 days, p=0.007). + Compared to placebo, AZLI improved CFQ{R by 5 points (scored out of 100), p=0.02; improved FEV 1 by 6.3%, p=0.001; and reduced sputum PA density by a small but significant amount. + There was no advantage taking AZLI three times a day compared to twice. + The medication was well tolerated.
Results
Critique + AZLI seems to be effective in patients already on inhaled tobramycin, so may have a role as an add{on therapy. + In relation to the study's primary endpoint, it is not clear that every exacerbation was due to PA infection and needed antipseudomonal antibiotics, some of them may have been viral or due to other bacterial organisms such as Staphylococcus aureus. + The work with this drug continues, and at the time of writing (November 2008) did not receive FDA approval. 
Non{invasive ventilation

Case{control study
Acute renal failure (5) What is already known? + CFTR is expressed in the kidney but its function is unknown and CFTR mutations are not associated with renal dysfunction. + In the UK, the incidence of acute renal failure (ARF) in patients with CF is estimated to be 4.6-10.5 cases per 10,000 CF patients per year, which means approximately 3-7 new cases of ARF each year. 4 In children, there is a 100-fold greater risk of ARF in CF compared to normal children.
Methods + ARF was defined as raised plasma creatinine for age with or without oliguria. + Previous national survey identified 24 confirmed cases from 20 centres, and these were matched for age and gender with patients from the UK CF Trust national database to identify risk factors.
Results
+ Of 24 patients with ARF, 21 (88%) had received an intravenous (IV) aminoglycoside at the time of their episode or in the previous week compared with 3/42 (7%) controls (odds ratio 82, 95% confidence interval 5-1427, p<0.001). + In the year prior to the ARF, significantly more cases had received IV gentamicin 19/24 (79%) vs 1/42 (2%) controls, p<0.001. + The numbers receiving IV tobramycin were similar: 9/24 (38%) cases vs 16/42 (38%) controls. + A known risk factor for ARF was present in 18/24 (75%) cases vs 7/42 (17%) controls. These included prior renal disease, CF{related diabetes, acute dehydration or long{term treatment with nephrotoxic drugs. + Any excess risk due to use of IV cephalosporin could not be calculated as all receiving it also had been given an aminoglycoside. + There was no risk associated with the use of nebulized aminoglycosides or colistin.
Critique + Original survey probably an underestimate of ARF so incidence may be even higher. + This is clearly a significant problem and many more patients with CF may have subclinical renal impairment. + Some methodological problems highlighted in accompanying editorial, particularly with only 42/96 controls being assessed. 5 + Nevertheless highlights importance of identifying potentially reversible risk factors before using aminoglycosides. + Should we stop using intravenous gentamicin?
It is no longer our first{choice aminoglycoside at Royal Brompton Hospital paediatric CF Unit. + Authors suggest an annual formal measure of glomerular filtration rate might be considered which sounds a good idea if logistics allow.
fibrosis. Am J Respir Crit Care Med 2008;177:995-1001
It is known that the flora inside CF lungs is multiple and varied, and that anaerobic conditions exist within the mucus. Sputum samples were collected from 50 stable adults with CF and bronchoalveolar lavage (BAL) fluid from 10 children with CF. Additionally, induced sputum was collected from 20 healthy adults. Specimens were analysed for presence of anaerobic bacteria. High numbers of anaerobes (Prevotella, Veillonella, Propionibacterium and Actinomyces genera) were isolated from 42/66 (64%) adult sputum samples, and similar numbers were found in the BAL samples of children. Although anaerobes were also isolated from 16/20 normal adults, they were present in much smaller numbers, and were generally different species to those in CF patients. Chronic infection with P. aeruginosa significantly increased the likelihood of finding anaerobes. All isolates were susceptible to meropenem. It is quite possible some of these anaerobes are causing infection and inflammation, and consideration should be given to including them in antibiotic regimens.
Preschool lung function (7) . The lung function of the CF infants was no different to the healthy infants while aged <6 months, but in those older than 6 months the mean FEV 0.5 Z score was 1.15 lower (p<0.001). The deficit in mean FEV 0.5 Z score increased by 0.77 per year of age. This deficit was not accounted for by pulmonary inflammation, as markers were no different for those less than compared to those over 6 months of age. Lung function was no different in those with positive microbiology compared to this with no organisms isolated. This study implies that even with early diagnosis and initiation of CF therapies in specialist centres, lung function deteriorates within the first 6 months.
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